Clinical Trial Update: A Single Ascending Dose Study of HM17321 in Healthy Adult Participants [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose study of HM17321 in healthy adults, evaluating safety and pharmacokinetics in the context of obesity-related conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• HM17321

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Obesity, Obese | Phase 1 | Status: RECRUITING